Evaluation of Compliance With Treatment by Genvoya in HIV Post-exposure Prophylaxis (NCT02998320) | Clinical Trial Compass
CompletedPhase 3
Evaluation of Compliance With Treatment by Genvoya in HIV Post-exposure Prophylaxis
France101 participantsStarted 2017-03-10
Plain-language summary
This study measures the proportion of enrolled patients taking the uninterrupted HIV post-exposure prophylaxis Genvoya for four weeks
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* an age above 18 years
* consultation within 48 hours following a risk of HIV transmission (blood or sexual contact)
* indication for HIV post-exposure prophylaxis (according to French guidelines)
* person able to understand the nature of the study
* person who signed his consent form to participate in the study
Exclusion Criteria:
* person exposed to HIV risk from person infected by HIV, whose therapeutic history justifies the prescription of another combination of antiretroviral drugs
* contraindications to the prescription of Genvoy
* other medical contraindications
* person infected by hepatitis B virus
* pregnant or lactating woman
What they're measuring
1
Proportion of patients taking the uninterrupted HIV post-exposure prophylaxis for four weeks
Timeframe: Day 28
Trial details
NCT IDNCT02998320
SponsorGroupe d'Etude sur le Risque d'Exposition des Soignants aux Agents Infectieux